Regulation of human phosphatidylinositol-specific phospholipase c-like enzyme
OwnerSophia Kossidainventor
Life of this patent
Estimating the term…
Abstract
Reagents which regulate human phosphatidylinositol-specific phospholipase C-like enzyme and reagents which bind to human phosphatidylinositol-specific phospholipase C-like enzyme gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, cancer, peripheral and central nervous system diseases, and chronic obstructive pulmonary disease.
Claims71
An isolated polynucleotide encoding a PI-PLC-like enzyme polypeptide and being selected from the group consisting of:
- a) a polynucleotide encoding a PI-PLC-like enzyme polypeptide comprising an amino acid sequence selected form the group consisting of:
- amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO:
- 2;
- and
- the amino acid sequence shown in SEQ ID NO:
- 2.
- b) a polynucleotide comprising the sequence of SEQ ID NOs:
- 1 or 4;
- c) a polynucleotide which hybridizes under stringent conditions to a polynucleotide specified in (a) and (b);
- d) a polynucleotide the sequence of which deviates from the polynucleotide sequences specified in (a) to (c) due to the degeneration of the genetic code;
- and
- e) a polynucleotide which represents a fragment, derivative or allelic variation of a polynucleotide sequence specified in (a to (d).
A cDNA encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.
An expression vector comprising a polynucleotide which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.
A host cell comprising an expression vector which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.
A purified polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.
A fusion protein comprising a polypeptide having the amino acid sequence shown in SEQ ID NO:2.
A method of producing a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising the steps of:
- culturing a host cell comprising an expression vector which encodes the polypeptide under conditions whereby the polypeptide is expressed;
- and
- isolating the polypeptide.
A method of detecting a coding sequence for a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising the steps of:
- hybridizing a polynucleotide comprising 11 contiguous nucleotides of SEQ ID NOS:1 or 4 to nucleic acid material of a biological sample, thereby forming a hybridization complex;
- and
- detecting the hybridization complex.
A method of detecting a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising the steps of:
- contacting a biological sample with a reagent that specifically binds to the polypeptide to form a reagent-polypeptide complex;
- and
- detecting the reagent-polypeptide complex.
A method of screening for agents which can modulate the activity of a human PI-PLC-like enzyme, comprising the steps of:
- contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of:
- (1) amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO:2 and (2) the amino acid sequence shown in SEQ ID NO:2;
- and
- detecting binding of the test compound to the polypeptide, wherein a test compound which binds to the polypeptide is identified as a potential agent for regulating activity of the human PI-PLC-like enzyme.
A method of screening for agents which modulate an activity of a human PI-PLC-like enzyme, comprising the steps of:
- contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of:
- (1) amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO:2 and (2) the amino acid sequence shown in SEQ ID NO:2;
- and
- detecting an activity of the polypeptide, wherein a test compound which increases the activity of the polypeptide is identified as a potential agent for increasing the activity of the human PI-PLC-like enzyme, and wherein a test compound which decreases the activity of the polypeptide is identified as a potential agent for decreasing the activity of the human PI-PLC-like enzyme.
A method of screening for agents which modulate an activity of a human PI-PLC-like enzyme, comprising the steps of:
- contacting a test compound with a product encoded by a polynucleotide which comprises the nucleotide sequence shown in SEQ ID NOS:1 or 4;
- and
- detecting binding of the test compound to the product, wherein a test compound which binds to the product is identified as a potential agent for regulating the activity of the human PI-PLC-like enzyme.
A method of reducing activity of a human PI-PLC-like enzyme, comprising the step of:
- contacting a cell with a reagent which specifically binds to a product encoded by a polynucleotide comprising the nucleotide sequence shown in SEQ ID NOS:1 or 4, whereby the activity of a human PI-PLC-like enzyme is reduced.
A pharmaceutical composition, comprising:
- a reagent which specifically binds to a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2;
- and
- a pharmaceutically acceptable carrier.
A pharmaceutical composition, comprising:
- a reagent which specifically binds to a product of a polynucleotide comprising the nucleotide sequence shown in SEQ ID NOS:1 or 4;
- and
- a pharmaceutically acceptable carrier.
A pharmaceutical composition, comprising:
- an expression vector encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2;
- and
- a pharmaceutically acceptable carrier.
A method of treating a PI-PLC-like enzyme disfunction related disease, wherein the disease is selected from cancer, peripheral or central nervous system disease, chronic obstructive pulmonary disease or asthma, comprising the step of:
- administering to a patient in need thereof a therapeutically effective dose of a reagent that modulates a function of a human PI-PLC-like enzyme, whereby symptoms of the PI-PLC-like enzyme disfunction related disease are ameliorated.
Dependencies are inferred from the claim text.